| Identification | Back Directory | [Name]
Darunavir-D9 | [CAS]
1133378-37-6 | [Synonyms]
TMC-114-d9
UIC-94017-d9
Darunavir-D9
Darunavir-d9
[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl-d9)amino]-2-hydroxy-1-(phenyl-methyl)propyl]carabamic Acid (3R,3aS,6aR)-Hexahydrofuro[2,3-b]-furan-3-yl Ester
[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl-d9)amino]-2-hydroxy-1-(phenyl-methyl)propyl]carabamic Acid (3R,3aS,6aR)-Hexahydrofuro[2,3-β]-furan-3-yl Ester | [Molecular Formula]
C27H37N3O7S | [MDL Number]
MFCD09840303 | [MOL File]
1133378-37-6.mol | [Molecular Weight]
547.664 |
| Chemical Properties | Back Directory | [Appearance]
Off-White Amorphous Solid | [Melting point ]
74-760C | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
Off-White to Pale Beige |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Amorphous Solid | [Uses]
Labeled Darunavir, intended for use as an internal standard for the quantification of Darunavir by GC- or LC-mass spectrometry. | [Uses]
Second generation HIV-1-protease inhibitor; structurally similar to amprenavir. Antiviral | [Description]
Darunavir-d9 is intended for use as an internal standard for the quantification of darunavir (Item Nos. 15866 | 31083) by GC- or LC-MS. Darunavir is an HIV-1 protease inhibitor. It is active against HIV-1LAI in MT-2 cells (IC50 = 3 nM) with a cytotoxic concentration (CC50) of 74.4 μM. Darunavir is also active against wild-type and multidrug-resistant clinical isolates of HIV-1 in phytohemagglutinin-activated peripheral blood mononuclear cells (PHA-PBMCs; IC50s = 3 and 3-29 nM, respectively). It inhibits cell-free diffusion and cell-to-cell spread of HIV-1 in Jurkat cell populations (IC50s = 2.5 and 2.8 nM, respectively). Formulations containing darunavir have been used in combination therapy for the treatment of HIV. | [References]
[1] YASUHIRO KOH. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.[J]. Antimicrobial Agents and Chemotherapy, 2003: 3123-3129. DOI: 10.1128/aac.47.10.3123-3129.2003
[2] BOGHUMA KABISEN TITANJI. Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells.[J]. Retrovirology, 2013, 10: 161. DOI: 10.1186/1742-4690-10-161 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|